# Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration

> **NCT03777254** · PHASE1 · COMPLETED · sponsor: **RemeGen Co., Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **BIOLOGICAL:** RC28-E

## Key facts

- **NCT ID:** NCT03777254
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-07
- **Primary completion:** 2019-08-20
- **Final completion:** 2019-08-20
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03777254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03777254, "Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03777254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*